Retatrutide is a novel triagonist peptide that simultaneously targets three critical metabolic receptors: Glucagon-like peptide-1 (GLP-1) Glucose-dependent insulinotropic polypeptide (GIP) Glucagon Originally developed for clinical research into obesity and metabolic disorders, retatrutide is designed to support extensive scientific exploration of: Weight reduction Improved glucose management Enhanced metabolic function What Key Benefits Does Retatrutide Offer
A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result
And for people with no prior substance use disorder, did GLP-1 drugs reduce their risk of developing one across all major addictive substances: alcohol, opioids, cocaine, cannabis and nicotine
Melanotan-2: High nausea rates (~38%)
GLP-1 Active ELISA Kit GLP-1 Background Glucagon-like peptide-1 ( GLP-1 ) is a 30 amino acid long peptide deriving from the tissue-specific posttranslational processing of proglucagon